Madrigal Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Madrigal Pharmaceuticals, Inc. carries a market capitalization of 12.50B, placing it among publicly traded companies globally. Its enterprise value stands at 11.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.50B |
| Enterprise Value | 11.91B |
Share Statistics
Madrigal Pharmaceuticals, Inc. currently has 23.09M shares outstanding.
| Shares Outstanding | 23.09M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 10.82, and the price-to-book ratio stands at 23.68.
| PE Ratio | N/A |
| PS Ratio | 10.82 |
| PB Ratio | 23.68 |
| P/TBV Ratio | 24.01 |
| P/FCF Ratio | -74.63 |
| P/OCF Ratio | -70.26 |
Enterprise Valuation
| EV / Sales | 9.28 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Madrigal Pharmaceuticals, Inc. maintains a current ratio of 3.20, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 66.40, indicating elevated leverage, while an interest coverage ratio of -10.19 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.20 |
| Quick Ratio | 2.76 |
| Debt / Equity | 66.40 |
| Debt / EBITDA | -1.08 |
| Interest Coverage | -10.19 |
Financial Efficiency
| Return on Equity (ROE) | -53.31 |
| Return on Assets (ROA) | -28.77 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.34 |
Stock Price Statistics
Madrigal Pharmaceuticals, Inc.'s stock has gained approximately 19.23314% over the past 52 weeks. The 50-day moving average sits at 529.59, while the 200-day moving average is 515.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | 19.23314% |
| 50-Day Moving Average | 529.59 |
| 200-Day Moving Average | 515.30 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Madrigal Pharmaceuticals, Inc. generated 1.28B in revenue and converted that into -325.09M in net income, yielding earnings per share of -12.57. EBITDA reached -321.10M, while operating income came in at -322.61M.
| Revenue | 1.28B |
| Gross Profit | 1.17B |
| Operating Income | -322.61M |
| Pretax Income | -325.09M |
| Net Income | -325.09M |
| EBITDA | -321.10M |
| EBIT | -322.61M |
| Earnings Per Share (EPS) | -12.57 |
Balance Sheet
Madrigal Pharmaceuticals, Inc. holds 838.75M in cash and equivalents against 347.75M in total debt, resulting in a net debt position of 48.07M. Total book value stands at 523.72M, with working capital of 824.98M providing operational flexibility.
| Cash & Cash Equivalents | 838.75M |
| Total Debt | 347.75M |
| Net Debt | 48.07M |
| Equity (Book Value) | 523.72M |
| Book Value Per Share | 22.68 |
| Working Capital | 824.98M |
Cash Flow
Madrigal Pharmaceuticals, Inc. produced -197.72M in operating cash flow over the past twelve months. After subtracting -11.57M in capital expenditures, free cash flow totaled -209.28M - equivalent to -8.09 per share.
| Operating Cash Flow | -197.72M |
| Capital Expenditures | -11.57M |
| Free Cash Flow | -209.28M |
| FCF Per Share | -8.09 |
Margins
Madrigal Pharmaceuticals, Inc. operates with a gross margin of 91.48, reflecting its pricing power and cost economics. The operating margin of -25.13 and net profit margin of -25.32 provide insight into operational efficiency.
| Gross Margin | 91.48 |
| Operating Margin | -25.13 |
| Pretax Margin | -25.32 |
| Profit Margin | -25.32 |
| EBITDA Margin | -25.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2.02 |
| FCF Yield | -1.34 |
Stock Splits
Madrigal Pharmaceuticals, Inc.'s most recent stock split took place on July 25, 2016 with a 35:1 split ratio.
| Last Split Date | 7/25/2016 |
| Split Ratio | 35:1 |
Scores
Madrigal Pharmaceuticals, Inc. posts an Altman Z-Score of 8.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.76 |